Pharmacologic therapy for pulmonary artery hypertension.

摘要: Purpose of review Pulmonary arterial hypertension (PAH) is a disease that carries significant mortality left untreated. This article aims to pharmacotherapeutics for PAH. Recent findings PAH-specific therapies have evolved over the last three decades and expanded from one therapy in 1990s 14 FDA-approved medications. Current are directed at restoring imbalance vasoactive mediators include nitric oxide, endothelin prostacyclin. Although these agents effective as monotherapy, recent trials promulgated strategy upfront combination therapy. The availability oral prostacyclin agonists has also allowed treatment options. Risk assessment vital guiding PAH patients. There ongoing focus on targeting pathological mechanisms via novel repurposing existing drugs. Summary an array medications available Prudent maximize effect can improve morbidity mortality. reviews data supporting attempts outline approach patient management.